100 related articles for article (PubMed ID: 24903194)
1. The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
Fujita H; Matsukura S; Watanabe T; Komitsu N; Watanabe Y; Takahashi Y; Kambara T; Ikezawa Z; Aihara M
Br J Dermatol; 2014 Dec; 171(6):1585-8. PubMed ID: 24903194
[No Abstract] [Full Text] [Related]
2. Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Inoue Y; Saito T; Tsuruoka Y; Sato K; Nishio Y; Suzuki Y; Kato M; Isobe Y; Sakai H; Takahashi M; Miura I
Thromb Res; 2013 Oct; 132(4):493-4. PubMed ID: 24050827
[No Abstract] [Full Text] [Related]
3. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome.
Nakajima S; Watanabe H; Tohyama M; Sugita K; Iijima M; Hashimoto K; Tokura Y; Nishimura Y; Doi H; Tanioka M; Miyachi Y; Kabashima K
Arch Dermatol; 2011 Sep; 147(9):1110-2. PubMed ID: 21931056
[No Abstract] [Full Text] [Related]
4. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.
Mori S; Hickey A; Dusza SW; Lacouture ME; Markova A
J Am Acad Dermatol; 2019 Mar; 80(3):608-616. PubMed ID: 30612984
[TBL] [Abstract][Full Text] [Related]
5. TNF-α as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS).
Uno H; Kabashima K; Tohyama M; Watanabe T; Hashimoto K; Iijima M; Sueki H; Watanabe H
J Dermatol Sci; 2014 May; 74(2):177-9. PubMed ID: 24517870
[No Abstract] [Full Text] [Related]
6. A case of drug reaction with eosinophilia and systemic symptoms induced by ethambutol with early features resembling Stevens-Johnson syndrome.
Kim JY; Sohn KH; Song WJ; Kang HR
Acta Derm Venereol; 2013 Nov; 93(6):753-4. PubMed ID: 23584150
[No Abstract] [Full Text] [Related]
7. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
8. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
[TBL] [Abstract][Full Text] [Related]
9. [Expression of high mobility group box-1 in the lung tissue and serum of patients with pulmonary tuberculosis].
Yang XM; Yang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):497-500. PubMed ID: 24262084
[TBL] [Abstract][Full Text] [Related]
10. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
11. The role of intracellular high-mobility group box 1 in the early activation of Kupffer cells and the development of Con A-induced acute liver failure.
Yang Q; Liu Y; Shi Y; Zheng M; He J; Chen Z
Immunobiology; 2013 Oct; 218(10):1284-92. PubMed ID: 23706499
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
13. Drug reaction with eosinophilia and systemic symptoms: a clinicopathological study of six cases at a teaching hospital in midwestern Brazil.
Correa-de-Castro B; Paniago AM; Takita LC; Murback ND; Hans-Filho G
Int J Dermatol; 2016 Mar; 55(3):328-34. PubMed ID: 26329991
[No Abstract] [Full Text] [Related]
14. Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure.
Lehloenya RJ; Isaacs T; Nyika T; Dhana A; Knight L; Veenstra S; Peter J
J Allergy Clin Immunol Pract; 2021 Jan; 9(1):582-584.e1. PubMed ID: 32835874
[No Abstract] [Full Text] [Related]
15. Systemic involvement of high-mobility group box 1 protein and therapeutic effect of anti-high-mobility group box 1 protein antibody in a rat model of crush injury.
Shimazaki J; Matsumoto N; Ogura H; Muroya T; Kuwagata Y; Nakagawa J; Yamakawa K; Hosotsubo H; Imamura Y; Shimazu T
Shock; 2012 Jun; 37(6):634-8. PubMed ID: 22392147
[TBL] [Abstract][Full Text] [Related]
16. High-mobility group box-1 protein determination in postmortem samples.
Palmiere C; Augsburger M; Mangin P
Forensic Sci Int; 2014 Jun; 239():103-6. PubMed ID: 24763129
[TBL] [Abstract][Full Text] [Related]
17. Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS).
Miyagawa F; Nakamura Y; Miyashita K; Iioka H; Himuro Y; Ogawa K; Nishimura C; Nishikawa M; Mitsui Y; Ito Y; Ommori R; Mori Y; Asada H
J Dermatol Sci; 2016 Aug; 83(2):151-4. PubMed ID: 27174092
[No Abstract] [Full Text] [Related]
18. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
19. Drug Rash with eosinophilia and systemic symptoms versus Stevens-Johnson Syndrome--a case that indicates a stumbling block in the current classification.
Wolf R; Davidovici B; Matz H; Mahlab K; Orion E; Sthoeger ZM
Int Arch Allergy Immunol; 2006; 141(3):308-10. PubMed ID: 16940741
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group box 1 as a surrogate prognostic marker in dogs with systemic inflammatory response syndrome.
Yu DH; Nho DH; Song RH; Kim SH; Lee MJ; Nemzek JA; Park J
J Vet Emerg Crit Care (San Antonio); 2010 Jun; 20(3):298-302. PubMed ID: 20636982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
